Worth reading carefully the UK's motivation to prioritise and commision this study (not investigtor-led) and then read it in context with associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/... Have fun ! 😃
Clinical effectiveness of procalcitonin- or C-reactive protein-guided antibiotic discontinuation protocols for adult patients who are critically ill with sepsis: a rapid systematic review and meta-analysis
www.manchester.ac.uk/about/news/t...
As @ics-updates.bsky.social updates #SOA25 congress draws to a close in Birmingham, Professor Paul Dark @darknatter.bsky.social of manchester.ac.uk emphasises the importance of this charity’s priority setting exercise in ensuring that patient needs are addressed by future sepsis research programmes
New from @jomcpeake.bsky.social @iculone.bsky.social @darknatter.bsky.social and colleagues from @sepsisresearch.bsky.social the full publication of the Sepsis Research priorities.
These set out the research priorities from established sepsis survivors, families, carers and healthcare professionals
We believe there is no such thing as a negative result - JAMA Editors agree, thankfully 👏
More resesrch results from UK critical care 👏
Please consider responding to this important survey following on from publication of the ADAPT-Sepsis trial
jamanetwork.com/journals/jam...
#IDsky #Medsky #ICUsky #Ansky 🧪
Have your say - an invitation to complete this important survey to inform UK implementation sespsis patient care research in PCT-guided antibiotic duration. www.qualtrics.manchester.ac.uk/jfe/preview/... @benmorton.bsky.social @ics-updates.bsky.social @criticalcarereviews.com
Editor’s choice from the February 25 issue.
➡️ Camrelizumab With Chemotherapy in Patients With Early or Locally Advanced TNBC
➡️ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
➡️ Essential Thrombocythemia: A Review; and more.
ja.ma/4hR14SI
#JAMA #MedSky
@davidaharrison.bsky.social ?
The third trial result for #CCR25 in Titanic Belfast in June is the UK-Rox Trial
Evaluating the clinical & cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in ICU
Register via the QR code or on the CCR website
criticalcarereviews.com/meetings/ccr25
Aim for 2025
Schöni Wiehnachte 🇨🇭 🎄 ♥️ ❄️
Detailed trial process evaluation coming soon - at least what was possible during the complexity of an unexpected global pandemic and the aftershock.
Kathy announced it day 2 - good move!
Thanks - I had dark hair at the start of this!
This is the very first part of a programme. You're will hear more about our trial process evaluation and health economic analysis early in 2025 - then a good go at bringing our data into the pool of open label trial results - remember our work also included intervention concealment.
Thanks Nick. Our motivation was to address a tight brief from the public funded, government run UK research sector, with mandated 3 arm rct including standard care and one of each, daily pct or crp discontinuation protocols. We wanted to add more quality to the evidence and, of course, MA in time.
Thanks Ben, explanation - data linkage with NHS was a nightmare, got this from our team on the way to the conference - you couldn't make it up. We'll find a way to disseminate somehow - but the 90-all cause is in the secondary outcomes.
@criticalcarereviews.com
Congratulations to the newly announced PROFESSOR Rob MacSweeney. Richly deserved for a modest person who works tirelessly in support of improving care of the critically ill through world leadership and creativity for clinical research dissemination with real impact. 👏 Prof.
... and also meet our funder's pre-specified brief of testing two biomarker protocols in a 3 arm rct.
Agree Lars, it's going to be how we get to understand all of this to progress care. I would also say that there are a number of open label pct trials out there that will need to be considered as a body of work - our trial was an attempt to add to knowledge with an intervention concealment strategy
Due to persistent challenges with data linkage for trials in the UK, we didn't get this KM plot into the final online manuscript, but we were able to show @CCR Down Under yesterday . The end of the 90-day follow-up was in September 2024.
See above Jack
It's a superiority trial with sample size estimate to detect a 1 day reduction in total antibiotic duration to day 28 for intervention(s) vs control. We were able to monitor safety (28-day all cause mortality)for this sample size with the stated NI margin. + 90-day all cause mortality was reported.
Chief Investigator @darknatter.bsky.social shares insights from the #ADAPTsepsistrial at #CCRdownunder
@adaptsepsis @jama.com
Congratulations @darknatter.bsky.social and team!
Absolutely fantastic work from @darknatter.bsky.social and team. Looking forward to a deep dive into the paper!
#ccrdownunder24
